Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

ADC Therapeutics (ADCT) Other Gross PP&E Adjustments (2019 - 2026)

ADC Therapeutics has reported Other Gross PP&E Adjustments over the past 8 years, most recently at -$1.2 million for Q1 2026.

  • Quarterly results put Other Gross PP&E Adjustments at -$1.2 million for Q1 2026, down 144.09% from a year ago — trailing twelve months through Mar 2026 was -$1.2 million (down 144.09% YoY), and the annual figure for FY2025 was -$13.0 million, down 0.98%.
  • Other Gross PP&E Adjustments reached -$1.2 million in Q1 2026 per ADCT's latest filing, up from -$13.0 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $4.9 million in Q2 2025 and bottomed at -$22.4 million in Q4 2022.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$2.8 million (2022), compared with a mean of -$4.5 million.
  • The largest annual shift saw Other Gross PP&E Adjustments plummeted 11218.46% in 2022 before it skyrocketed 911.86% in 2025.
  • Over 5 years, Other Gross PP&E Adjustments stood at -$22.4 million in 2022, then surged by 30.99% to -$15.5 million in 2023, then grew by 17.1% to -$12.8 million in 2024, then fell by 0.98% to -$13.0 million in 2025, then surged by 90.74% to -$1.2 million in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for ADCT at -$1.2 million in Q1 2026, -$13.0 million in Q4 2025, and $4.9 million in Q3 2025.